Cas No.: | 634911-47-0 |
SMILES: | CNC1=CC=C(/C=C/C2=NC3=CC=C(OCCF)C=C3O2)C=C1 |
Formula: | C18H17FN2O2 |
M.Wt: | 312.34 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | In Vitro BF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42. In Vivo Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, 18F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t1/2=24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [18F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding. |